LATEST NEWS

Improving Your Coding for Value-Based Plans with HCC
Hierarchical Condition Category (HCC) is the risk-adjustment methodology for Medicare used by all Medicare Advantage plans. HCCs stratify patient risk and predict the costs for capitated payments. This is because patients with only minor health conditions are expected to have averaged medical costs in the near future. Why is it important for a busy family physician to be aware of how they use these codes? Read more in the blog post, , by Christopher Scuderi, DO, and Judella Haddad, MD.

The Importance of Certification

To ensure osteopathic family medicine remains a viable profession for decades and centuries to come, ACOFP members must come together as a community to encourage residents and medical students to pursue osteopathic certification through AOBFP. Read more about the importance of certification—and why maintaining osteopathic distinctiveness is vital to the profession—in the latest  by Joel M. Feder, DO, FACOFP dist.

ICYMI: ACOFP Virtual Inauguration Ceremony
Please join us in welcoming Nicole Bixler, DO, MBA, FACOFP, as the fourth female president in ACOFP history. She was inaugurated during a  last Thursday. The ceremony featured a to ACOFP Immediate Past President, Robert C. DeLuca, DO, FACOFP dist.; the official swearing in by Past President Jeffrey S. Grove, DO, FACOFP dist.; Dr. Bixler’s inspirational ; and a  sharing words of support and encouragement from ACOFP members.

HHS Announces New Phase 3 General Distribution
On October 1, the Department of Health and Human Services—through the Health Resources and Services Administration—announced a new  from the Provider Relief Fund (PRF) that will provide $20 billion to eligible providers. 

Call for Nominations: ACOFP Governor
ACOFP is accepting  for the position of Governor for the 2021–2022 . The position will be elected by the ACOFP Congress of Delegates in March 2021, according to the Nominating Committee process. View The deadline for submissions is December 15, 2020.

WHO Study on Effectiveness of Repurposed Drugs

The world’s largest randomized  on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19. Interim results from the Solidarity Therapeutics Trial, coordinated by the World Health Organization, indicate that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.